Novartis AG (NVS)

The stock has a good momentum. Novartis AG (NVS) is a mediocre stock to choose.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of he...

News

Angeles Wealth Management LLC Has $351,000 Stake in Novartis AG (NYSE:NVS)

Zolmax Angeles Wealth Management LLC reduced its position in shares of Novartis AG (NYSE:NVS - Free Report) by 5.6% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 3,301 shares of the...\n more…

Sanofi pays $110M upfront for late-stage radioligand therapy, setting up rivalry with Novartis

FierceBiotech.com - Biotech Sanofi pays $110M upfront for late-stage radioligand therapy, setting up rivalry with Novartis\nntaylor\nThu, 09/12/2024 - 04:55...\n more…

Dorsey & Whitney Trust CO LLC Has $1.54 Million Stake in Novartis AG (NYSE:NVS)

Zolmax Dorsey Whitney Trust CO LLC lowered its stake in Novartis AG (NYSE:NVS - Free Report) by 4.4% in the second quarter, according to the company in its most recent disclosure with the Securities...\n more…

This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday

Benzinga Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Considering buying NVS stock?\n more…

Novartis AG (NOVN) Receives a Buy from UBS

TipRanks Financial Blog In a report released today, Matthew Weston from UBS maintained a Buy rating on Novartis AG (NOVN - Research Report), with a price target of CHF111....\n more…

Wedbush Securities Inc. Decreases Stock Holdings in Novartis AG (NYSE:NVS)

Zolmax Wedbush Securities Inc. cut its holdings in Novartis AG (NYSE:NVS - Free Report) by 17.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The...\n more…